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Glycolytic regulation of cell rearrangement
in angiogenesis
Bert Cruys1,2, Brian W. Wong1,2, Anna Kuchnio1,2, Dries Verdegem1,2, Anna Rita Cantelmo1,2,
Lena-Christin Conradi1,2, Saar Vandekeere1,2, Ann Bouche´1,2, Ivo Cornelissen1,2, Stefan Vinckier1,2,
Roeland M. H. Merks3,4, Elisabetta Dejana5,6,7, Holger Gerhardt8,9,10, Mieke Dewerchin1,2,
Katie Bentley5,11,* & Peter Carmeliet1,2,*
During vessel sprouting, endothelial cells (ECs) dynamically rearrange positions in the sprout
to compete for the tip position. We recently identified a key role for the glycolytic activator
PFKFB3 in vessel sprouting by regulating cytoskeleton remodelling, migration and tip cell
competitiveness. It is, however, unknown how glycolysis regulates EC rearrangement
during vessel sprouting. Here we report that computational simulations, validated by
experimentation, predict that glycolytic production of ATP drives EC rearrangement by
promoting filopodia formation and reducing intercellular adhesion. Notably, the simulations
correctly predicted that blocking PFKFB3 normalizes the disturbed EC rearrangement in high
VEGF conditions, as occurs during pathological angiogenesis. This interdisciplinary study
integrates EC metabolism in vessel sprouting, yielding mechanistic insight in the control of
vessel sprouting by glycolysis, and suggesting anti-glycolytic therapy for vessel normalization
in cancer and non-malignant diseases.
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D
uring angiogenesis, a blood vessel sprout is guided by a
migrating ‘tip’ cell and elongated by proliferating ‘stalk’
cells. Lateral DLL4/Notch signalling underlies tip cell
selection and regulates the response of endothelial cells (ECs) to
the pro-angiogenic signal vascular endothelial growth factor
(VEGF). Indeed, by inducing VEGF receptor 2 (VEGFR2)
signalling, VEGF activates the EC expressing the highest levels
of this receptor. However, VEGFR2 signalling also upregulates
DLL4 expression, which activates the Notch1 receptor on
neighbouring cells. This, in turn, lowers VEGFR2 expression,
thereby rendering these cells less responsive to VEGF, as such
creating a ‘salt & pepper’ (S&P) pattern of activated and inhibited
ECs1,2. Here we use ‘tip’ and ‘stalk’ to refer to a cell’s relative
position in the sprout, and ‘active/activated’ and ‘inhibited’ to
indicate the cellular state. These states are dynamically
interchangeable, allowing ECs in a sprout to overtake each
other (termed EC rearrangement), thereby ensuring that the most
competitive EC leads the sprout3,4.
Glycolysis promotes EC competitiveness for the tip position5.
ECs that are instructed to become a stalk cell can still overtake
their wild-type (WT) neighbours and become a tip cell through
the overexpression of the glycolytic regulator 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase 3 (PFKFB3)5. Genetic and
pharmacological inhibition of PFKFB3 reduces sprouting5,6 and
the capacity of ECs to reach the sprout tip5, while PFKFB3
overexpression induces opposite effects5,7. Furthermore, PFKFB3
knockdown (PFKFB3KD) in ECs reduces filopodia and
lamellipodia formation5. Finally, blockade of glycolysis inhibits
pathological angiogenesis6–8.
EC rearrangement depends on differential VE-cadherin-
dependent intercellular adhesion and differential formation of
polarized junctional cortex protrusions (referred to as ‘cortical
protrusions’). These processes drive EC intercalation and depend
on VEGF-Notch signalling9. While VEGF promotes VE-cadherin
endocytosis10, EC motility2, forward–rear cell polarity3, weak
intercellular adhesion and serrated junctions9, Notch signalling
impairs EC rearrangement4 by rendering cells more adhesive and
by suppressing cortical protrusions, resulting in ‘straighter’
junctions9. EC shuffling thus requires actin remodelling11,12,
which is highly ATP consuming13 as it can require up to 50% of
cellular ATP levels14,15. In ECs, glycolytic production of ATP is
essential for the formation of cytoskeletal protrusions5 and the
stability of intercellular junctions16. In addition, endocytosis of
cadherins, which determines the available cadherin levels at the
plasma membrane and hence also adhesion, relies on ATP in
epithelial cells17–20. However, it remains unknown how glycolysis
regulates EC rearrangements during vessel sprouting and, in
particular, whether PFKFB3-driven glycolytic production of
ATP controls filopodia extension, intercellular adhesion (via an
effect on VE-cadherin endocytosis), and formation of cortical
protrusions during EC rearrangement.
Here we investigate the link between EC rearrangements and
metabolism. By combining computational modelling with
experimentation, we identify mechanistic insights into how
PFKFB3-driven glycolysis steers EC rearrangements during vessel
sprouting, and show that targeting glycolysis in ECs normalizes
cell rearrangement and vessel disorganization in disease, meriting
further attention for therapy. Throughout this study, we follow an
integrated ‘symbiotic’ approach21, iteratively using in vitro and
in vivo experiments to validate and refine our computational
model and to confirm in silico predictions.
Results
MemAgent-Spring computational model characteristics. For
reasons of clarity, we first introduce some key features of the
memAgent-Spring computational model (MSM) before
describing our new extensions to the model (for full details see
Supplementary Note). The MSM is a spatiotemporal, agent-based
model in which an in silico vessel sprout contains ECs,
whose membranes consist of many small computational agents
(‘memAgents’) that can move on an interlinked surface mesh.
The memAgents are connected in the mesh by springs,
representing the actin cortex underneath the cell membrane9.
The MSM recapitulates VEGF/Notch-dependent tip/stalk cell
selection as follows: ECs sensing higher levels of VEGF have more
active VEGFR2 signalling. These ‘activated’ cells express higher
DLL4 levels, which activate Notch receptors and thereby ‘laterally
inhibit’ VEGFR2 signalling in adjacent cells (Fig. 1a,b)22.
VEGFR2 signalling also increases local actin polymerization,
thereby promoting the formation of dynamic filopodia. Since
filopodia express VEGFR2 (ref. 23), a positive feedback is
generated, whereby VEGFR2 stimulates filopodia to move
further into the VEGF gradient, amplifying its own signalling
and subsequent DLL4 presentation to neighbouring ECs24.
Hence, filopodia act as amplifiers of DLL4/Notch-mediated
lateral inhibition in the MSM, a form of active perception to
probe the environment and arrive at a selection of activated/
inhibited states22,25,26. Recently, we incorporated a modified
implementation of the Cellular Potts model27 into the MSM to
allow differential adhesion and cortical protrusion formation,
which together drive EC rearrangement9.
The MSM-ATP model. Tip cells are more glycolytic than stalk
cells, as they express higher levels of PFKFB3 (ref. 5) (Fig. 1a).
Indeed, when PFKFB3KD and WT ECs are mixed in a 1:1 ratio in
mosaic EC spheroids, PFKFB3KD ECs contribute to only 22.4% of
the tip cells (instead of the expected 50% if they would be as
competitive as WT cells)5 (Fig. 1c). Likewise, when PFKFB3KD
and WT ECs are mixed in a 9:1 ratio, PFKFB3KD cells contribute
to only 66.8% of the tip cells (instead of the expected 90%)5. We
therefore modelled another level of regulation of vessel sprouting
as a new extension to the MSM, namely glycolytic ATP
production, in order to assess how these ATP levels regulate
EC rearrangement. We upgraded the latest MSM version to the
MSM-ATP by making three model effectors driving EC migration
(filopodia formation, cortical protrusions, intercellular adhesion)
dependent on glycolytic ATP levels. We therefore included the
following modifier constants: (i) kFIL to modify the filopodia
effector (EFIL), reflecting the in silico probability of filopodia
extension; (ii) kCOR to alter the cortex effector (ECOR), reflecting
the in silico probability of forming cortical protrusions that
facilitate ECs to move relative to each other; and (iii) kADH
to change the intercellular adhesion effector (EADH) (Fig. 1b;
Methods section and Supplementary Note). Intercellular adhesion
is determined by the amount of VE-cadherin on the cell surface,
which itself depends on VE-cadherin endocytosis, a process
that is stimulated by VEGFR2 signalling10. Thus, an EC with
high VEGFR2 activity (VEGFR2 phosphorylation) has more
VE-cadherin endocytosis, which reduces its adhesion and thereby
promotes EC motility. Therefore, EADH classifies cells as either
strongly or weakly adhesive based on the cell’s VEGFR2 activity.
We also considered other MSM-ATP effectors that might
depend on glycolytic ATP, such as the amount of actin that
ECs can accumulate, the stability of filopodia, and the
phosphorylation and glycosylation status of VEGFR2.
However, since PFKFB3 inhibition did not change VEGFR2
phosphorylation5 or VEGFR2 glycosylation6, and changing
filopodia stability or the amount of actin did not match all
features assessed during the elimination process (Supplementary
Fig. 1), we did not further consider these processes.
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Simulating EC rearrangement in mosaic vessel sprouts. Our
overall objective was to explore whether the competitive
disadvantage of PFKFB3KD ECs could be explained by an effect of
reduced glycolytic ATP production on filopodia formation and/or
EC rearrangement. To identify via which ATP-dependent effector
mechanism(s) PFKFB3-driven glycolysis regulates tip cell com-
petition, we varied the aforementioned MSM-ATP effectors,
alone or in combination, to simulate the PFKFB3KD phenotype in
silico (referred to as ‘isPFKFB3KD’). Single mechanisms (in which
only one effector was modified) included EFIL, ECOR and EADH,
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while combinatorial mechanisms enclosed EFIL/COR, EFIL/ADH,
ECOR/ADH and EALL. We refer to isPFKFB3KD cells simulated
by these respective mechanisms as follows: isPFKFB3KD-FIL,
isPFKFB3KD-COR, isPFKFB3KD-ADH, isPFKFB3KD-FIL/COR,
isPFKFB3KD-FIL/ADH, isPFKFB3KD-COR/ADH and isPFKFB3KD-ALL.
As depicted in the study outline (Supplementary Fig. 1), we
first calibrated the single-effector mechanisms by varying the kFIL,
kCOR and kADH constants over wide ranges in isPFKFB3KD cells
and assessed how these competed in mosaic sprouts with random
placement of in silico WT (isWT) and isPFKFB3KD ECs using an
established approach9 (Fig. 1d). We will refer to mosaic sprouts
consisting of isPFKFB3KD and isWT ECs, mixed in a 1:1 and 9:1
ratio, as 1:1 or 9:1 isPFKFB3KD:isWT sprouts, respectively.
Simulations were performed with sprouts containing 10 ECs, with
2 cells per cross-section (Fig. 1e, Supplementary Movie 1). To
match the simulations with the in vitro results, we developed a
computational method to quantify tip cell competition in silico,
similar to how tip cell competition is measured manually in vitro
(see Methods section).
We then tested the potential of these mechanisms to explain
the PFKFB3KD phenotype by comparing them to published
experimental data, and eliminated those that did not match
(Supplementary Fig. 1). This was done to identify the mechan-
ism(s) that explained best the role of glycolytic ATP in EC
rearrangement and filopodia formation and to ensure the model’s
predictive capacity. Thereafter, we predicted EC behaviour in
experimentally untested conditions, such as Notch inhibition and
pathological VEGF levels, and subsequently experimentally
validated these in silico predictions to ultimately identify the
most representative isPFKFB3KD mechanism (Supplementary
Fig. 1).
Regulation of tip cell competition by MSM-ATP effectors.
When modifying each effector mechanism alone in 1:1
isPFKFB3KD:isWT sprouts, we identified k values for each
effector that yielded the exact same tip cell contribution as
observed experimentally (Fig. 2a-c, full lines). In fact, for
isPFKFB3KD-FIL and isPFKFB3KD-COR ECs, multiple k values
matched the experimental data. Since we could not select a single
k value, optimally fitting the experimental data, we used an
additional criterion that the k values also had to match 9:1
PFKFB3KD:WT EC spheroid data. Also for this ratio, we found
k values that matched the experimental data (Fig. 2a–c, dotted
lines). When combining the 1:1 and 9:1 isPFKFB3KD:isWT
results, we identified a k value for each single effector mechanism
that optimally matched the experimental results (Fig. 2a–c;
Supplementary Note Table 1).
Since it is likely that glycolytic ATP simultaneously affects
multiple effectors, we also simulated combinatorial effector
mechanisms. To avoid bias, we varied, for each respective
combination, the k values of each individual effector contributing
to this combination by approximately a comparable extent
(Supplementary Note). We identified k values for every effector
combination that matched the experimental 1:1 and 9:1
PFKFB3KD:WT competition data (Fig. 2d,e; Supplementary
Note Table 1).
These results show that the MSM-ATP is suited to simulate the
PFKFB3KD competition defect. Also, these simulations predicted
that all three ATP-dependent effectors could mediate the
role of PFKFB3-driven glycolysis in tip cell competition.
We next evaluated another key phenotype of PFKFB3KD ECs
(impaired filopodia formation) to distinguish between the effector
mechanisms (Supplementary Fig. 1).
Regulation of filopodia formation by MSM-ATP effectors.
Intuitively, the EFIL mechanism was expected to match
the PFKFB3KD filopodia defect. However, EADH and ECOR
might also indirectly affect filopodia formation, since they affect
intercellular junctions, and junction size determines DLL4/Notch
lateral inhibition, which restricts filopodia formation24. While
isPFKFB3KD-FIL cells indeed formed fewer and shorter filopodia,
isPFKFB3KD-COR or isPFKFB3KD-ADH cells formed filopodia
normally (Fig. 3a–f, Supplementary Movies 2–4). We therefore
discarded the single ECOR and EADH mechanisms, as they
failed to recapitulate this essential trait of PFKFB3KD ECs
(Supplementary Fig. 1).
Among the combinatorial effector mechanisms, only those in
which EFIL was affected, matched the PFKFB3KD filopodia defect
(Fig. 3g–n, Supplementary Movies 5–8). We therefore discarded
ECOR/ADH and retained EFIL, EFIL/COR, EFIL/ADH or EALL as
potential mechanisms (Supplementary Fig. 1). We then studied
whether we could further refine the search for the most plausible
mechanism by focusing on intercellular adhesion and cortical
protrusion formation, other potentially ATP-requiring processes.
PFKFB3KD increases intercellular heterogeneity. We recently
reported that heterogeneous EC behaviour, based on differential
VE-cadherin-dependent intercellular adhesion and differential
formation of cortical protrusions, drives EC rearrangement
during vessel sprouting9. Since the VEGFR2/Notch signalling axis
steers these processes, inhibition of Notch signalling by the
g-secretase inhibitor DAPT removes all intercellular hetero-
geneity in a sprout and causes all ECs to become active
and weakly adhesive9. Notably, PFKFB3 blockade reduces
DAPT-induced vascular hypersprouting to normal levels6.
We thus simulated DAPT-treated 1:1 isPFKFB3KD:isWT
sprouts (modelled by removing Notch1-signalling between all
Figure 1 | General concept of the study. (a) Schematic of a sprout showing the differential properties of its ECs, which are activated or inhibited. Active
ECs inhibit adjacent cells through Dll4/Notch signalling, are migratory and competitive for the tip. They overtake other ECs (cell rearrangement) due to
higher VE-cadherin endocytosis rates (which makes them weakly adhesive) and formation of junctional cortical protrusions. (b) Scheme depicting the
effectors modified in the memAgent-Spring ATP model (MSM-ATP) and the signalling pathways included in the MSM-ATP. EFIL (representing filopodial
F-actin), ECOR (referring to cortical actin), and EADH (denoting intercellular adhesion) determine respectively, the probability of filopodia extension, the
formation of polarized junctional protrusions and cellular adhesion levels, determined by VE-cadherin endocytosis. The pink lines indicate the ATP effector
links that were investigated. (c) Schematic drawing of the in vitro EC spheroid assay. Cells with different genotypes (and corresponding colours) are
cultured in a sphere and allowed to sprout for 24 hours upon growth factor stimulation. Subsequently, the colour of the cell at the tip is counted for each
sprout, allowing to quantify the tip cell contribution as shown in the graph for 1:1 WTGFP:WTRED and PFKFB3KD/GFP:WTRED mosaic spheroids. Data are
mean±s.e.m.; n¼ 30 from 3 donors; **Po0.01; Fisher’s exact test; adapted from ref. 5 with permission from Elsevier. (d) Screenshots of MSM-ATP
simulations, showing how cell positions change over time and how, similar as in the in vitro assay, the genotype (colour) of the cell at the end of the in silico
experiments can be assessed. The red arrows represent the movement of the cell to its next position in the next simulation screenshot. (e) Scheme
illustrating how MSM-ATP simulations are performed using vessel sprouts consisting of ten ECs. Each colour represents a different EC. ATP, adenosine
triphosphate; DLL4, delta-like 4; NICD, Notch1 intracellular domain; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3; VE-cadherin,
vascular endothelial cadherin; VEGF, vascular endothelial growth factor; VEGFR2, VEGF receptor 2.
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cells) and studied whether the retained effector mechanisms
promoted intercellular heterogeneity in the sprout.
First, we evaluated whether differential VE-cadherin-
dependent adhesion was increased in DAPT-treated isPFKFB3KD
cells. As VEGFR2 signalling determines VE-cadherin endo-
cytosis10, we assessed VE-cadherin-dependent intercellular
adhesion by determining the fraction of cells with low VEGFR2
activity (strongly adhesive cells). These simulations revealed that
EFIL and EADH increased adhesion, but ECOR did not (Fig. 4a;
Supplementary Fig. 2a). Indeed, since lowering EFIL reduced the
number and length of filopodia (Fig. 3a,b), and filopodia amplify
VEGF signalling by expressing VEGFR2 (ref. 22), it decreased
VEGFR2 signalling in isPFKFB3KD cells and thus increased
adhesion. Moreover, increasing EADH reduced VE-cadherin
endocytosis and therefore increased adhesion.
The number of strongly adhesive isPFKFB3KD cells was
consequently increased for each remaining mechanism
(Fig. 4a). Thus, these cells had a disadvantage to reach the
sprout’s front as compared with the less-adhesive isWT cells, and
therefore contributed less to the tip upon DAPT treatment,
similar to the PFKFB3KD competition defect in control conditions
(Fig. 4b). However, isPFKFB3KD-ALL cells contributed more to
the tip than the cells of the other isPFKFB3KD mechanisms
(Fig. 4b), because one of their contributing effectors (ECOR) did
not increase adhesion and because the kFIL, kCOR and kADH values,
obtained for isPFKFB3KD-ALL cells to match the experimental
data (Fig. 2d,e), were relatively low (Supplementary Note).
Thus, filopodia formation and intercellular adhesion mediated
the effects of PFKFB3-driven glycolysis on differential adhesion in
the sprout, required for EC rearrangement.
Next, we focused on cortical protrusions, which are
formed excessively when Notch signalling is inhibited by
DAPT9. Lowering ECOR in isPFKFB3KD-FIL/COR and
isPFKFB3KD-ALL cells reduced cortical protrusion formation in
DAPT-treated 1:1 isPFKFB3KD:isWT sprouts (Supplementary
Fig. 2b). Hence, modifying EFIL/COR and EALL modestly increased
the differential formation of cortical protrusions. In contrast,
modifying EFIL or EFIL/ADH did not reduce cortical protrusion
formation in DAPT conditions (Supplementary Fig. 2b).
Since the reduction in cortical protrusion formation was
similar in isPFKFB3KD-FIL/COR and isPFKFB3KD-ALL cells
(Supplementary Fig. 2b) and as the competitiveness of
isPFKFB3KD-ALL cells was higher (Fig. 4b), cortical protrusion
formation was not expected to contribute to the PFKFB3-driven
effect on cellular heterogeneity in the DAPT-treated sprout.
To validate in vitro these computational predictions, we treated
1:1 PFKFB3KD:WT EC spheroids with DAPT. We observed that
PFKFB3KD ECs still contributed less to the tip position (Fig. 4c).
Hence, only the isPFKFB3KD-FIL, isPFKFB3KD-FIL/COR and
isPFKFB3KD-FIL/ADH mechanisms correctly predicted the experi-
mental outcome. We thus discarded the isPFKFB3KD-ALL mech-
anism and only retained isPFKFB3KD-FIL, isPFKFB3KD-FIL/COR
and isPFKFB3KD-FIL/ADH as mechanisms that potentially
explained the role of glycolytic ATP in EC rearrangement
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(Supplementary Fig. 1). Overall, the MSM-ATP predicted that
PFKFB3-driven glycolysis affects vessel sprouting through effects
on filopodia formation, alone or together with cortical protrusion
formation or adhesion.
PFKFB3KD reduces VE-cadherin turnover. To validate the
regulation of intercellular VE-cadherin-dependent adhesion
by glycolytic ATP, we measured VE-cadherin expression and
dynamics in cultured PFKFB3KD ECs. PFKFB3KD did not change
VE-cadherin expression levels (Supplementary Fig. 2c). We thus
quantified VE-cadherin mobility and turnover (that is,
reappearance of VE-cadherin at the cell surface after prior
endocytosis) at junctions by fluorescence recovery after photo-
bleaching (FRAP). As the magnitude of fluorescence recovery was
similar in PFKFB3KD and WT ECs, PFKFB3KD did not change
the mobile VE-cadherin fraction in the plasma membrane
(Fig. 4d,e). However, the fluorescence recovery rate was lower in
PFKFB3KD ECs, as revealed by the longer halftime, indicating
that VE-cadherin turnover was reduced by PFKFB3KD (Fig. 4d,f).
These findings confirmed the in silico predicted role of
VE-cadherin-dependent intercellular adhesion in the PFKFB3KD
phenotype.
High VEGF levels perturb EC rearrangement. We then
simulated pathological angiogenesis to explore via which
effector mechanisms PFKFB3 affected vessel sprouting in
non-physiological conditions, given that PFKFB3 blockade
inhibits ocular and inflammation-induced neovascularization6,7.
Dysfunctional EC rearrangement is a feature of pathological
angiogenesis, as demonstrated in mouse models characterized by
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high VEGF levels such as oxygen induced retinopathy
and cancer9,28. Before exploring whether PFKFB3 blockade
normalized EC rearrangements in pathological conditions, we
simulated a 2-fold (‘2x VEGF’) and 10-fold (‘10x VEGF’) increase
in VEGF concentrations in the MSM-ATP. We selected these
conditions since VEGF levels in tumours generally increase by
2- to 10-fold in early and late stages of tumour progression29–32,
and analysed cell shuffling and the S&P pattern formation of
isWT sprouts during 24 h of sprouting.
We assessed cell shuffling by tracking the number of cell–cell
overtakes and the duration that individual cells spend at the
sprout’s tip (with respect to their initial position). The sprout’s
ability to acquire and maintain a S&P pattern of activated
and inhibited cells reflects DLL4/Notch-mediated signalling
(Supplementary Fig. 3a, Supplementary Movie 9). We therefore
developed a new method of scoring S&P patterns that accounted
for their dynamic nature, since cells in the sprout shuffle and
change neighbours, continuously disrupting and re-establishing
S&P patterns. We assessed the average and maximal time that a
S&P pattern was maintained, as well as the intermittent time
between subsequent S&P patterns, called the stabilizing time.
Similar to previous observations with the MSM22,24, we found
using the MSM-ATP that the higher the VEGF levels were,
the more synchronized and oscillatory the cells of an isWT
sprout became. This implies that the cells were all active or
inhibited, rather than organized in an alternating S&P pattern
(Supplementary Fig. 3b,c; Supplementary Movie 10). This
abnormal behaviour was reflected by: (i) a lower number of
cell–cell overtakes (Supplementary Fig. 3d, Supplementary
Movies 11); (ii) a decreased ability to form and maintain a
S&P pattern (Supplementary Fig. 3e–g); (iii) reduced cell
rearrangement in the sprout (Supplementary Fig. 3h–j); and
consistent herewith (iv) a reduced chance for rear cells to reach
the tip position (Supplementary Fig. 3k). We used these results in
high VEGF conditions to assess the effects of in silico
pharmacological PFKFB3 blockade on this dysfunctional EC
rearrangement, and to evaluate whether normalization of EC
rearrangement might underlie the beneficial effects observed
upon in vivo pharmacological PFKFB3 blockade6. We therefore
explored if any of the three residual effector mechanisms could
normalize the perturbed EC rearrangement in pathological
conditions.
PFKFB3 blockade is predicted to normalize EC rearrangement.
We first re-calibrated the MSM-ATP to ensure that it matched
the impaired in vitro EC migration and sprouting upon PFKFB3
blockade by 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one
(3PO) or 7,8-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one6
(YN1; Supplementary Note Table 2). Since pharmacological
drugs indiscriminately target all cells of an angiogenic sprout,
we modelled in silico pharmacological PFKFB3 inhibition
(isPFKFB3PI) by using non-mosaic sprouts in which all cells
experience PFKFB3 inhibition.
We then assessed whether any of the remaining effector mechan-
isms (isPFKFB3PI-FIL, isPFKFB3PI-FIL/COR, isPFKFB3PI-FIL/ADH)
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could reverse the abnormal EC behaviour in high VEGF
conditions. Before simulating the (very) high VEGF conditions
(as observed in tumours), we confirmed the accuracy of our
modelling approach by simulating a 1.44-fold increase in VEGF
levels, reflecting the increase in VEGF in choroid neovasculariza-
tion (CNV)33. All aforementioned EC perturbations were
completely normalized, except for the positional interchanges in
isPFKFB3PI-FIL/COR sprouts (Supplementary Fig. 4a–e). Hence,
these results suggest that a normalized EC rearrangement
seemingly underlies the reduced pathological angiogenesis upon
PFKFB3 blockade in the CNV model6.
When studying 2 VEGF levels, we observed that the
abnormal EC features were partially normalized in an
isPFKFB3PI-FIL sprout. Indeed, isPFKFB3PI-FIL cells, positioned
initially at the rear of the sprout, had a higher chance of
reaching the front (Supplementary Fig. 5a) and more
frequently overtook neighbouring cells (Fig. 5a). In addition,
by reducing filopodia formation, lowering EFIL impaired the
responsiveness to VEGF and thereby increased the Notch-
driven heterogeneity between isPFKFB3PI-FIL cells (Fig. 5b–d).
This counteracted the perturbed S&P patterning, explaining why
isPFKFB3PI-FIL cells overall had an increased ability to reach and
maintain stable S&P patterns.
Similar findings were obtained for isPFKFB3PI-FIL/ADH cells
(Fig. 5a–d; Supplementary Fig. 5a). However, the stabilizing time
for these cells was reduced less than for isPFKFB3PI-FIL cells
(Fig. 5d). This was likely due to the lower kFIL value used to match
the PFKFB3KD:WT EC competition data (Fig. 2d,e). Qualitatively,
similar findings regarding the ability to form and maintain S&P
patterns were obtained for isPFKFB3PI-FIL/COR cells (Fig. 5b-d),
though the stabilizing time for these cells was reduced the
least (Fig. 5d). However, reducing ECOR in addition to EFIL
counteracted the normalization effect of reducing EFIL on the
overtaking and cell shuffling behaviour (Fig. 5a; Supplementary
Fig. 5a) by impairing EC migration (Supplementary
Fig. 5b). Thus, the EFIL and EFIL/ADH mechanisms normalized
the abnormal EC rearrangement the best. In contrast, the EFIL,
EFIL/COR and EFIL/ADH mechanisms failed to normalize the
abnormal EC features in 10 VEGF levels (Supplementary
Fig. 6a–e). In fact, isPFKFB3PI-FIL/COR sprouts showed even an
increased, albeit not significantly, stabilizing time and a decreased
number of overtakes, thus further disorganizing rather than
normalizing EC behaviour.
Overall, the prediction that EC disorganization was normalized
only minimally for isPFKFB3PI-FIL/COR sprouts excluded EFIL/COR
as a plausible mechanism to explain the PFKFB3KD phenotype,
since PFKFB3 blockade reduces pathological angiogenesis6.
Hence, taken the results of all in silico and in vitro experiments
together, the mechanisms that best explain the PFKFB3KD
phenotype across all conditions are EFIL and EFIL/ADH.
However, since the VE-cadherin turnover was reduced upon
PFKFB3KD in the FRAP experiment (Fig. 4d-f), EFIL/ADH is the
most likely mechanism to reproduce the complete PFKFB3KD
phenotype. While previous studies documented a role for
filopodia in tip cell selection22 and for PFKFB3-driven
glycolysis in filopodia formation by tip cells5, this study
identified a previously unknown role for PFKFB3-driven
glycolysis in filopodia formation and intercellular adhesion
underlying EC rearrangement during vessel sprouting.
Combined PFKFB3/VEGF blockade normalizes vessel sprouting.
Since VEGF signalling regulates EFIL and EADH 9, and 3PO
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enhances the anti-angiogenic effect of a VEGF receptor kinase
inhibitor (SU5416) in physiological conditions6, we assessed
in silico whether blockade of both PFKFB3 and VEGF signalling
might be more efficient in normalizing the deregulated EC
rearrangement in pathological conditions (10VEGF). Since
SU5416 inhibits VEGFR2 phosphorylation34, we modelled the
anti-VEGF therapy by reducing VEGFR2 signalling activity
(Supplementary Note). This simulation predicted that an
anti-VEGF and anti-glycolytic treatment together were most
effective in normalizing EC behaviour (Fig. 6a–d; Supplementary
Fig. 7a, Supplementary Movies 12,13). A full rescue with the
combined treatment was observed when the VEGFR2 signalling
activity was decreased sixfold. Applying anti-VEGF therapy alone
in 10x VEGF levels was predicted to only partially normalize the
disorganized EC dynamics (Supplementary Fig. 7b-e). Hence,
the simulations predicted that combinatorial anti-glycolytic and
anti-VEGF treatment would normalize EC rearrangement in
disease.
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To validate this prediction experimentally, we tested whether
PFKFB3 blockade, as monotherapy and as combination therapy
with VEGF blockade, could normalize pathological vessels in two
established models of vessel disorganization, characterized by
structurally abnormal vessels with deregulated EC rearrange-
ments: (i) Matrigel plugs containing high amounts of VEGF35,
and (ii) retinas of postnatal day 5 (P5) mouse pups upon
intraocular injection of high VEGF amounts9,28. In the Matrigel
model, high VEGF levels induce the formation of structurally
abnormal and disorganized vessels, characterized by tortuosity
and poor pericyte coverage35. Monotherapy with 3PO or SU5416
improved the association between pericytes and ECs (vessel
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maturation, a sign of vessel normalization36) (Fig. 7a-c,e), and
tended to reduce vessel tortuosity (Fig. 7f). However, these vessel
normalization effects were most prominent and statistically
robust upon combined treatment with 3PO plus SU5416
(Fig. 7d-f).
In the retina model, intraocular VEGF injection evokes marked
structural vessel abnormalities and deregulated EC rearrange-
ments, and has therefore become an increasingly used model to
study these processes9,23,28,37. Indeed, intraocular VEGF injection
evokes vessel expansion28, reduces the number of tip cells at the
vascular front (a consequence of disrupted DLL4/Notch
signalling)28, and changes the differential VE-cadherin pattern
at EC junctions so that clustered regions are formed, within
which ECs are either active or inhibited9, all signs of EC
rearrangement defects9,26. VEGF indeed enlarged vessel size and
decreased the number of tip cells (Fig. 8a,b,f,g). Monotherapy
with 3PO or SU5416 partially restored the vessel width and the
number of tip cells (Fig. 8c,d,f,g), but the largest normalization
effect was obtained with the combination of 3PO plus SU5416
(Fig. 8e-g). We then quantified the VE-cadherin pattern at
individual EC junctions using established image analysis
software9, classifying junctions in a graded scale from ‘active’
(irregular, serrated junctions with vesicular, diffuse appearance)
to ‘inhibited’ (with a straighter and less vesicular morphology)
(Fig. 8h). Injection of VEGF reduced the VE-cadherin junctional
heterogeneity, inducing the formation of clusters containing
either active or inhibited ECs (Fig. 8i-k,q,r). Monotherapy with
3PO or SU5416 partially normalized the VE-cadherin junctional
pattern (becoming more heterogeneous again, but still containing
small clustered regions of active or inhibited junctions)
(Fig. 8l-o,q,r), while the combination treatment with 3PO plus
SU5416 completely normalized the VE-cadherin junctional
heterogeneity (Fig. 8p-r). Taken together, these in vivo results
validated the in silico predictions.
Discussion
Through an integrated combination of computational and experi-
mental approaches, we identified the combinatorial
EFIL/ADH mechanism as the only mechanism that matches the
endothelial PFKFB3KD phenotype across all conditions.
PFKFB3KD thus reduces EC rearrangement and tip cell competi-
tion by increasing adhesion and reducing filopodia formation.
This previously unknown regulation of intercellular adhesion by
PFKFB3 was validated experimentally. Hence, through modelling,
we obtained a mechanistic explanation for the reduced tip cell
competitiveness of PFKFB3KD ECs. In addition to cytoskeletal
remodelling leading to filopodia formation, glycolysis also
regulates adhesion in sprouting ECs. Uncovering such regulation
of closely linked individual mechanisms by PFKFB3 is difficult
to achieve experimentally, conditions in which computational
modelling can greatly assist experimental research38. Moreover,
the model predicts that treatment with a PFKFB3 blocker
normalizes perturbed EC rearrangements in pathological
conditions. We verified this prediction in two established
models of vessel disorganization, and observed that PFKFB3
blockade indeed evoked normalization of EC rearrangements
during pathological angiogenesis in vivo.
We previously documented that PFKFB3KD impairs filopodia
formation of tip cells5. However, we did not characterize the
mechanism via which this filopodia defect regulated vessel
sprouting. Here we show that reduced formation of filopodia
upon PFKFB3KD has a substantial impact on EC rearrangement
during vessel sprouting. Indeed, isPFKFB3KD-FIL ECs extend
fewer and shorter filopodia, thereby affecting VEGFR2 activation
and shifting the cells to a more adhesive phenotype.
Hence, isPFKFB3KD-FIL ECs matched three key experimentally
observed defects of PFKFB3KD ECs, that is, impaired tip cell
competition, reduced filopodia formation, and decreased
pathological angiogenesis.
In addition, the simulations predicted unknown effects of
reducing filopodia in high VEGF conditions, such as the (partial)
normalization of the perturbed EC rearrangement and signalling
dynamics. Indeed, reducing EFIL increased the number of cell-cell
overtakes and the likeliness of the rear cells to reach the tip
position. Moreover, since filopodia act as signalling sensors
that amplify lateral inhibition, reducing EFIL in high VEGF
conditions impaired the EC responsiveness to VEGF and thereby
increased the Notch-driven intercellular heterogeneity. The latter
mechanism counteracts the perturbed S&P patterning in high
VEGF conditions, explaining why isPFKFB3PI-FIL cells overall
had an increased ability to reach and maintain stable S&P
patterns.
Our simulation studies unveiled an unknown regulation by
PFKFB3-driven glycolysis of intercellular adhesion, which is
essential for EC rearrangement. In an isPFKFB3KD-ADH:isWT
sprout, the weakly adhesive isWT cells had an advantage, while
the strongly adhesive isPFKFB3KD-ADH cells had a disadvantage
to propel to the sprout’s front. Hence, isPFKFB3KD-ADH ECs
matched a key phenotypic defect of PFKFB3KD ECs, namely
impaired tip cell competition. In contrast, filopodia formation
was not affected. In high VEGF conditions, reducing EADH
together with EFIL also partially normalized the perturbed EC
rearrangement. This unexpected glycolytic regulation of inter-
cellular adhesion in a vessel sprout was experimentally validated
by our findings that PFKFB3KD lowered VE-cadherin turnover at
the cell surface of cultured contacting ECs.
Figure 8 | 3PO / SU5416 combo-therapy normalizes pathological angiogenesis. (a–e) Representative images of retinas ( 20 magnification) stained for
isolectinB4 (IB4) in normal conditions (nVEGF, a) and after VEGF injection (hVEGF, b-e). Pups were treated with DMSO (CTR, a,b), 3PO (c), SU5416 (d) or
3PO plus SU5416 (e). Note the widened vessel lumen and fewer tip cells at the vascular forefront upon VEGF injection (b), and the partial (c,d) and
complete (e) normalization by single or combined 3PO and SU5416 treatment. Scale bar, 50mm. (f,g) Quantification of vessel width (f) and tip cell number
at the retinal front (g). Data are mean±s.e.m.; n¼ 7 per condition; NS: not significant, *Po0.05, ***Po0.001 versus DMSO-treated vessels in normal
conditions. ###, Po0.001 versus DMSO-treated vessels in hVEGF. The statistical significance between the single or combined 3PO/SU5416 treatments is
also indicated (NS: not significant, *Po0.05, **Po0.01, ***Po0.001); Student’s t-test. a.u., arbitrary units. (h) VE-cadherin junction classification from
‘active’ (red; irregular/serrated morphology with vesicular/diffuse regions) to ‘inhibited’ (dark blue; straighter morphology and less vesicular staining). (i–p)
VE-cadherin morphology of retinal vessels was hand-classified according to the key in h, yielding VE-cadherin heat maps in normal conditions (nVEGF, i)
and upon VEGF injection (hVEGF, j–p) of pups, treated with DMSO (j,k), 3PO (l,m), SU5416 (n,o), or 3PO plus SU5416 (p). The colour(s) provide insight
into the extent of junctional heterogeneity of the vessels. Compared to the heterogeneous VE-cadherin pattern in nVEGF retinas (i), hVEGF induces
clusters of inhibited (j) or activated (k) ECs. These clusters are smaller upon 3PO (inhibited: l; active: m) or SU5416 monotherapy (inhibited: n; active: o)
and completely normalized to heterogeneous patterns upon combined 3PO plus SU5416 treatment (p). Scale bar, 20mm. (q,r) Prevalence of strongly
inhibited (q) or activated (r) VE-cadherin junctions in retinal vessels. Data are mean±s.e.m.; n¼ 5–9 per condition; NS, not significant, *Po0.05,
***Po0.001 versus nVEGF (black); #Po0.05, ##Po0.01 versus hVEGF (grey). The statistical significance between the single or combined 3PO/SU5416
treatments is also indicated (*Po0.05); One-tailed Wilcoxon rank-sum test for equal medians.
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How PFKFB3-driven glycolysis regulates VE-cadherin
adhesion remains to be determined, but we can speculate about
possible mechanisms. First, PFKFB3-driven glycolysis generates
ATP, which can be used to phosphorylate VE-cadherin
before endocytosis10, thus reduced ATP availability would result
in longer VE-cadherin exposure at the cell surface. Second,
VE-cadherin and the actin cytoskeleton are physically connected
via multiple adaptor proteins39,40. Since PFKFB3 controls
actin cytoskeleton remodelling5 and endocytosis requires
actin polymerization41, PFKFB3 might influence VE-cadherin
dynamics via actin.
The simulations in pathological conditions predicted that
blocking PFKFB3, via effects on filopodia formation and
intercellular adhesion, was capable of completely or partially
normalizing the perturbed EC rearrangement in silico, when
VEGF levels were elevated 1.44- and 2-fold, respectively. This is
in close agreement with findings that PFKFB3 blockade or loss in
ECs can inhibit pathological angiogenesis in ocular, inflamed and
malignant tissues6,7. Interestingly, the in silico CNV results
suggest that normalized EC dynamics might contribute to the
anti-angiogenic effect of PFKFB3 inhibition.
When vessels grow in pathological conditions, they are often
structurally highly abnormal, a phenomenon that has been best
studied in tumours, but is also relevant in ocular disease
and atherosclerosis36,42. Disorganized vessels are dilated and
tortuous, are covered by fewer pericytes, and are lined by an
irregular endothelium, characterized by hypermotile ECs with
excessive filopodia and deregulated EC rearrangements. Vessel
normalization is therefore emerging as a therapeutic paradigm to
restore tissue performance by improving vessel formation,
function and interaction with the microenvironment36,42. We
therefore simulated PFKFB3 blockade also in more extreme
VEGF levels (10 VEGF), corresponding with late-stage
tumours. However, in silico PFKFB3 or VEGFR2 blockade as
monotherapy was unable to completely normalize the perturbed
EC rearrangements in these conditions. This required a
combinatorial blockade of PFKFB3 plus VEGF signalling. Using
established models of vessel disorganization, we experimentally
validated these predictions in vivo by showing that a combination
treatment with 3PO plus SU5416 reduced vessel dilatation and
the numbers of tip cells at the vascular forefront, and restored
differential junctional patterning in high VEGF-treated retinas.
Moreover, we showed that this combined treatment normalized
vessel tortuosity and pericyte coverage in VEGF-containing
Matrigel plugs.
Our findings might be relevant in light of the emerging results
that intrinsic refractoriness and acquired drug resistance limit the
success of VEGF-targeted therapy in cancer and other diseases42.
As tumour vessels have weak and disorganized VE-cadherin
junctions9,43, strengthening these junctions by PFKFB3 plus
VEGF blockade would normalize the endothelium and tighten
the endothelial barrier, thereby constituting a stronger physical
barrier for cancer cells to escape. In addition, our findings may
also have implications for other disease conditions characterized
by disorganized blood vessels in general, such as in ocular
neovascularization, atherosclerosis and so on. Hence, our
simulations were not only instrumental in identifying cellular
mechanisms whereby PFKFB3-driven glycolysis regulates vessel
sprouting, but also predicted vessel normalization by targeting EC
metabolism (glycolysis).
Methods
Cell culture. Human umbilical venous endothelial cells (HUVECs, referred to as
‘ECs’) were isolated from umbilical cords of different donors44. Umbilical cords
were obtained from the Gynaecology Department of the University Hospital
Leuven, with approval of the Medical Ethical Commission of KU Leuven/
University Hospital Leuven, and informed consent was obtained from all subjects.
The umbilical vein was rinsed with 20ml DPBS (Gibco, Invitrogen, Life
Technologies, Ghent, Belgium) and subsequently incubated with 20ml warm
collagenase type 1 (2mgml 1 in 0.9% NaCl supplemented with 2mM CaCl2 and
1 antibiotics/antimycotics; Gibco, Invitrogen, Life Technologies) for 15min at
37 C. The collagenase and ECs were collected and the vein was rinsed two times
with EC culture medium. The collected fluid was filtered (40 mm nylon cell strainer,
BD Pharmingen 555289, Erembodegem, Belgium), centrifuged at 800 r.p.m. for
5min and resuspended in 15ml culture medium. The isolated ECs were used
between passage 1 and 5 and cultured in: (i) M199 medium (1mgml 1 D-glucose;
Gibco, Invitrogen, Life Technologies) supplemented with 20% fetal bovine serum
(Gibco, Invitrogen, Life Technologies), 2mM L-glutamine, 30mg l 1 endothelial
cell growth factor supplements, 10 unitsml 1 heparin (Sigma-Aldrich,
Bornem, Belgium), 100 IUml 1 penicillin and 100mgml 1 streptomycin,
or (ii) endothelial cell growth medium 2 (ECGM-2; Promocell, Germany)
supplemented with ECGM-2 SupplementMix C-39216 (Promocell, Germany).
ECs were cultured at 37 C and 5% CO2 and the growth medium was changed
every 48 h.
Lentiviral transductions. For all spheroid experiments, PFKFB3-targeting oligo-
nucleotides (shPFKFB3) cloned into the pLVX-shRNA2 vector (No. PT4052-5;
Clontech, Westburg BV, Leusden, The Netherlands) were used. A pRRL-mCherry
Red vector, kindly provided by M. Mazzone, was used to fluorescently mark WT
HUVECs. The full-length mouse VE-cadherin complementary DNA (cDNA) fused
to the enhanced green fluorescent protein (GFP) cDNA was kindly provided by
D. Vestweber (Max Planck Institute, Muenster, Germany) and was cloned into the
pRRLsin.PPT.CMV.MCS MM.Wpre lentiviral vector (pLenti-MP2; Addgene). For
PFKFB3 knockdown in the FRAP experiments, shPFKFB3 or scrambled control
oligonucleotides cloned into the PLKO.1-vector (Sigma-Aldrich) were used.
Lentiviruses were produced by transfection into 293T cells45. HUVECs were
co-transduced with VE-cadherin-GFP virus and shPFKFB3- or scrambled short
hairpin RNA (shRNA)-encoding PLKO virus. All lentiviruses were used at a
multiplicity of infection of 20. HUVECs were transduced overnight in the presence
of 0.5 mgml 1 polybrene (Sigma-Aldrich), washed three times and replenished
with fresh medium the next day. Transduced HUVECs were used in functional
assays at least 3–4 days post transduction.
EC spheroid assay. 1,000 transduced and/or control ECs were cultured overnight
as hanging drops in a 1:1 ratio in ECGM2 medium supplemented with 20% methyl
cellulose (Sigma-Aldrich) to form spheroids. The resulting spheroids were
embedded in a collagen matrix by overlaying them with 1 vol methyl cellulose
containing 40% fetal bovine serum and subsequent addition of 1/3 vol NaHCO3
(15.6mgml 1), 4/5 vol collagen (collagen type 1, rat tail extract, Merck Millipore,
Overijse, Belgium) and 2% vol NaOH (1M)46. The collagen solution containing
spheroids was aliquoted in 24-well plates and allowed to polymerize for
30min at 37 C. Next, ECGM2 medium containing the g-secretase inhibitor
N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT,
10 mM; Merck Millipore, Overijse, Belgium) or the corresponding control vehicle
(dimethyl sulfoxide (DMSO), Sigma-Aldrich) was added. Finally, 24 h after the
addition of the culture medium, the EC spheroids were fixed by adding an equal
volume of 4% paraformaldehyde at room temperature for 30min. Tip cell
contribution of WT (red) or shRNA-transduced ECs (green) was manually
analysed under a Zeiss Axiovert 40 CFL fluorescence microscope ( 40 objective)
(Carl Zeiss, Munich, Germany) (see also below).
FRAP analysis of HUVECs. ECs, co-transduced with lentiviral vectors expressing
VE-cadherin-GFP and shPFKFB3/scrambled shRNA, were seeded at a density of
100,000 cells per well into a eight-well m-slide (Ibidi 80826, Ibidi, Beloeil, Belgium),
coated with 0.1% gelatin (Sigma-Aldrich), for imaging on the next day. Live
imaging and photobleaching of VE-cadherin-GFP-positive ECs was performed
using a Zeiss LSM 780 (Axio Observer.Z1) confocal microscope (Carl Zeiss,
Munich, Germany) at  100 magnification while using an incubation chamber set
at 37 C and 5% CO2. Before photobleaching, four Z-stack images were acquired.
Then the GFP-fluorophore was bleached for 150 iterations using a 488-nm argon
laser at 100% laser power. Images were acquired at 135 acquisitions every 5 s for a
period of 10–13min using the Definite Focus System. Fluorescence intensities were
analysed using the ZEN microscope software version 2012 (Carl Zeiss). The
values of fluorescence intensities after photobleaching were normalized with the
fluorescence intensity before photobleaching and subsequently analysed in
Graphpad Prism v6.0f by performing a non-linear regression with one-phase
association. Only recovery curves with a R2 value 40.95 were taken into
consideration.
RNA analysis. RNA expression analysis was performed by Taqman quantitative
reverse transcriptase–PCR, which was read in MicroAmp Fast Optical 96-well
Reaction Plates (Applied Biosystems, Carlsbad, CA). The cDNA (2.5 ng ml 1), the
Taqman Fast Universal PCR Master Mix (Applied Biosystems) and the premade
primer mix with probe (final concentration of primers and probe were 900 and
250 nM, respectively; Applied Biosystems and IDT, Leuven, Belgium) were mixed
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on ice. Primer ID numbers were Hs.PT.56a.4732035 (VE-cadherin) and
Hs.PT.58.2145446 (HPRT). The samples were measured with the 7500 Fast
Real-Time PCR system (Applied Biosystems), using the following cycling
conditions: 20 s 95 C, 40 cycles of 95 C for 3 s and 30 s 60 C.
Animals. C57BL/6J or C57BL/6N mice were obtained from the KU Leuven
Animal Facility or were purchased from Charles River (Wilmington, MA, USA).
Animal procedures were approved by the Institutional Animal Care and Research
Advisory Committee (KU Leuven) and were performed in accordance with the
institutional and national guidelines and regulations.
Matrigel model of in vivo angiogenesis. Growth factor-reduced Matrigel
(Corning, New York, USA; 500 ml) supplemented with 200 ngml 1 VEGF-A 165
(VIB Protein Service Facility), 500 ngml 1 bFGF (Peprotech, London, UK) and
60Uml 1 heparin (Leo Pharma, Wilrijk, Belgium) was subcutaneously injected on
the back of C57BL/6J mice (protocol adapted from ref. 35). Pathological
vasculature was allowed to develop during 6 days, followed by 5 consecutive days of
treatment by intraperitoneal injection of control vehicle (DMSO, Merck Millipore,
Overijse, Belgium), 3PO (ChemBridge Corporation, San Diego, USA; 25mg kg 1
per day) and/or the VEGFR2 tyrosine kinase inhibitor SU5416 (Sigma-Aldrich;
10mg kg 1 per day). These doses of 3PO and SU5416 were determined in pilot
dose-response experiments. Three to five mice were used per group. Matrigel plugs
were collected and stained for CD105 and NG2 to analyse vessel tortuosity and
pericyte coverage.
Postnatal retinal angiogenesis model. 300 ng VEGF-A 165 (0.5 ml; VIB Protein
Service Facility) was injected into the eyes of P5 C57BL/6N pups using a Hamilton
micro-syringe9,23. Subsequently, the pups were treated by intraperitoneal injection
of control vehicle (DMSO, Merck Millipore, Overijse, Belgium), 3PO (ChemBridge
Corporation, San Diego, USA; 25mg kg 1) and/or the tyrosine kinase inhibitor
SU5416 (Sigma-Aldrich; 12mg kg 1). Seven pups were used per group. These
doses of 3PO and SU5416 were determined in pilot dose-response experiments.
Twenty hours after VEGF injection, pups were euthanized, eyes were enucleated
and processed for isolectinB4 and VE-cadherin staining.
Immunohistochemistry. Matrigel plugs were stained using the primary antibodies
anti-CD105/endoglin (1:50, R&D Systems, Minneapolis, MN, USA) and anti-
neural/glial antigen 2 (NG2, 1:200; Chemicon-Millipore, Merck, Germany) to
characterize ‘tumour’ vessels. Matrigel plugs were then incubated with the
appropriate fluorescently conjugated secondary antibodies (Alexa 568 or 647,
1:200, Molecular Probes, Invitrogen, Life Technologies). The Matrigel plugs were
imaged at a magnification of  20 using a Zeiss LSM 780 (Axio Observer.Z1)
confocal microscope (Carl Zeiss). Retinas were collected on P6 and fixed with
4% paraformaldehyde for 1 h at room temperature. They were subsequently
stained using the anti-VE-cadherin antibody9 (1:25, BD Pharmingen 555289,
Erembodegem, Belgium) and isolectinB4-Alexa antibody (1:100, Molecular Probes,
Invitrogen, Life Technologies)5. The secondary antibody targeting the anti-VE-
cadherin antibody was the appropriate fluorescently conjugated Alexa 488 antibody
(1:500, Molecular Probes, Invitrogen, Life Technologies). Retinas were imaged at
magnification  20 and  63 using a Zeiss LSM 780 (Axio Observer.Z1) confocal
microscope (Carl Zeiss).
VE-cadherin junctional activity. VE-cadherin junctional activity of retinas was
analysed by hand using the patching algorithm9. The algorithm processed each
optical plane of the z-stack of the confocal retinal images ( 63 magnification)
into random patches of 100 100 pixels based on a user-defined threshold for the
anti-VE-cadherin signal. The resulting patches were subsequently blindly presented
to the user who hand-classified the VE-cadherin morphology in each patch
according to the key shown in Fig. 8h. Next, the classified patches were used to
reconstruct images as three-dimensional-summed z-projections of the patch class
colour overlaid on the VE-cadherin staining. The resulting colour(s) give insight
into the extent of junctional heterogeneity of the vessels.
Vessel width of retinal blood vessels. To analyse the vessel width of the retinal
front, we imaged isolectinB4-stained retinas at a magnification of  5 using a Leica
DMI6000B inverted microscope (Leica Microsystems, Mannheim, Germany) and
measured the distance from the centre of the dissected retina to the retinal front.
The upper third of this distance of the retina lobes was subsequently used for
analysis. Vessel width was analysed using the RAVE tool 47.
Pericyte coverage in the Matrigel model. We analysed pericyte coverage of
blood vessels in Matrigel plugs by whole-mount staining for the pericyte marker
NG2 and the EC marker CD105, and by measuring the NG2þ area as a percentage
of the total CD105þ vessel area.
Blood vessel tortuosity in the Matrigel model. Blood vessel tortuosity was
scored semi-quantitatively by dividing  20 images, taken on a Zeiss LSM 780
(Axio Observer.Z1) confocal microscope (Carl Zeiss), in four equal quarters. The
CD105-stained vessel segments were then categorized into four distinct classes:
(i) highly tortuous; (ii) mildly tortuous; (iii) nearly straight; and (iv) completely
straight. A score was attributed to each image quarter and averaged per Matrigel
plug. The scoring was done in a blinded manner.
MSM-ATP development. The MSM of angiogenesis was used to study cellular
dynamics during angiogenesis. In the MSM, ECs are modelled as ECagents, which
consist of smaller memAgents that are connected by springs following Hooke’s law,
representing the actin cortex beneath the cell membrane22,24. These memAgents
allow localized responses to the environment such as the extension or retraction of
filopodia. The latest version of the model is extended with the Cellular Potts
Model27, allowing differential adhesion-based dynamics to occur9. The model is
well calibrated to in vitro and in vivo data and is well validated to simulate
VEGF/Dll4/Notch signalling, cell shape changes, filopodia, junctional movements
and EC rearrangement (for full details and methods see refs 9,22,24 and
Supplementary Note). To enable simulation of ATP-driven processes, the MSM
was extended with the modification that ATP levels govern actin and junctional
dynamics (called MSM-ATP) by modulating three different cellular effectors alone
or in combination. For each simulated mechanism the MSM-ATP effector(s) was
(were) changed with a constant k.
EFIL: varying the probability of filopodia extension
P filopodiað Þ ¼ ðCþ kFILÞ  V
0
m Mtot
Vmax
: ð1Þ
where: V
0
m represents the memAgent’s active VEGFR2, Mtot represents the current
total number of memAgents of the ECagent, Vmax represents an ECagent’s
maximal VEGFR2 capacity, C represents the strength of the VEGFR2-actin
activation signal
ECOR: varying the probability of junctional cortex protrusion formation
P CORð Þ ¼ 1
N
00
c
l
h i
þ kCOR ; if N 00col and flip polarised
0; otherwise
(
ð2Þ
where: N
00
c represents the ECagent’s effective active Notch level, l controls cellular
migratory capacity
EADH: changing the cellular adhesion levels
V
00
coZþ kADH ! strongly adhesive
V
00
c4Zþ kADH ! weakly adhesive

ð3Þ
where: V
00
c represents the ECagent’s effective active VEGFR2 level, Z represents a
calibrated threshold to classify cells as strongly or weakly adhesive
Quantifying tip cell competition. To compare the in silico simulations with the
in vitro EC spheroid assay results, we developed an analogical evaluation method
termed the ‘Artificial Brian’ analysis method. In the EC spheroid assay, sprouting is
stopped after 24 h by fixing the cells with paraformaldehyde (Carl Roth, Karlsruhe,
Germany). Next, phase contrast microscopy is used to check the shape of the
tip cell and whether it is attached to the sprout. Red and green fluorescence
microscopy is used to determine which cell is at the tip position. The latter is
determined by the relative position of cell bodies to each other rather than
taking into account cytoskeletal protrusions such as filopodia. Accordingly, for the
in silico simulations, we developed an analytical method to identify which cell is
spearheading the in silico sprout as tip cell. We assigned 10 grid sites, which can be
occupied by memAgents, to the front of the sprout, and then quantified how many
of the 10 grid sites were occupied by memAgents for each cell. The cell with the
most memAgents occupying the 10 grid sites was considered to be the tip cell, as
this cell moved its cell body the most to the front. In case these 10 front grid sites
were evenly occupied by different cells, the cell with the highest VEGFR2 activity
was considered to be the tip cell. Next, we thoroughly tested if there is a difference
in the relative contribution to the tip when the simulations are assessed at 24 h
(2,880 timesteps as 1 timestep¼ 30 s) or after the typical 125 h (15,000 timesteps)
analysis time point used in ref. 9. No difference was observed and we therefore used
the 125 h analysis time point as longer simulation runs would yield more
information regarding sprouting/overtaking behaviour.
Scoring of EC adhesive strength. At each simulation timestep, the levels of active
VEGFR2 (V
00
c parameter22), which represent the levels of phosphorylated VEGFR2,
are evaluated. These levels are then compared with a threshold in order to classify cells
as strongly or weakly adhesive in the MSM-ATP in a binary fashion (Z parameter9;
V
00
coZ: strongly adhesive, V 00c4Z: weakly adhesive). The adhesive strength as well as
the genotype (isWT versus isPFKFB3KD) of each cell is tracked and saved to an
output file, allowing us to link the adhesive strength to a cell’s properties and to
compare adhesion properties between sprouts in different conditions.
In silico migration. At each simulation timestep, an in silico cell’s centre of mass
(COM) is calculated and stored in the x, y and z direction by averaging their
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memAgents’ position in the respective directions. The COM in the x-direction
(COM_x; low and high COM_x values, respectively, represent the rear and front of
the sprout) is used to evaluate the distance covered by a cell. The absolute
difference in a cell’s COM_x values between two subsequent timesteps is stored and
added to the total migrated distance of that cell. As such, we track the distance each
cell covers during a simulation, allowing us to compare the migratory properties of
different cells (for example, isWT vs isPFKFB3KD) in similar/different conditions
(for example, VEGF levels).
S&P pattern scoring. At each timestep after the onset of cellular rearrangements
in the MSM-ATP (an initial stabilization period of 1,000 timesteps during which
no cell movement is allowed, to permit the formation of a stable S&P pattern of
active and inhibited cells9), all ECagents are tested for three properties: their active
levels of Dll4 and VEGFR2 and the status of their actin pool. First, the Dll4 and
VEGFR2 signalling activities of each ECagent are assessed to evaluate whether they
meet the respective thresholds to be classified as an activated cell. If so, its actin
pool will subsequently be assessed. If the actin threshold for activated cells is met,
the number of ‘sprout active cells’ is increased. However, to decrease the stringency
of the S&P pattern scoring (too much information about the stabilization and
maintenance of a S&P pattern would otherwise be lost), we introduce the term
‘stunted active cell’. This is a cell that meets the Dll4- and VEGFR2-signalling
activity thresholds but not the actin threshold. Also the number of ‘stunted active
cells’ is evaluated. If for the whole sprout, the number of ‘active cells’ (the sum of
‘stunted active cells’ and ‘sprout active cells’) equals 3 (that is, the number of ‘active
cells’ in an ideal S&P pattern in the used simulation set-up of 10 ECagents), a stable
S&P pattern is possibly obtained/maintained. Whether a S&P pattern is classified
as stable depends on the final test, which checks whether ‘active cells’ are adjacent
to each other. If the latter is true, the parameter recording the stabilizing time is
incremented with one timestep, as such tracking the intermittent time between two
subsequent S&P patterns. If not, a stable S&P pattern is obtained/maintained and
the time during which it is maintained is stored. If the S&P pattern is newly
generated, the time it took to stabilize into this pattern is used to calculate the
average stabilizing time of S&P patterns and the parameter used to track the
stabilizing time is reset to 0. Whenever the stable S&P pattern is lost, the time it
lasted is used to calculate the average S&P pattern time. Throughout the whole
simulation, all S&P pattern times are stored to eventually acquire the maximal time
a S&P pattern could be maintained.
Statistics. The data represent mean±s.e.m. of pooled experiments unless
otherwise stated. The tip cell competition graphs depict representative in vitro or
in silico experiments. Each in vitro experiment was performed at least 3 times and
for all in silico experiments at least 50 simulations were run (unless otherwise
specified). Each of these 50 simulations used a different random seed, which
determines the initial positioning of the cells (for example, WT and isPFKFB3KD
cells) in the sprout. Statistical significance for tip cell competition graphs was
calculated by performing Fisher’s exact test (contingency test; mutant (green) or
WT (red) present at tip). For all other graphs, statistical significance was calculated
by standard t-test unless otherwise specified. All statistical analyses were performed
in Graphpad Prism v6.0f. Po0.05 was considered significant. Throughout the
manuscript the following symbols for statistical significance are used: *Po0.05,
**Po0.01; ***Po0.001.
Data availability. The authors declare that the data supporting the findings of this
study are available within the article and its supplementary information files, or
from the corresponding authors upon request. The executable MSM-ATP software
as well as the patching algorithm are available on request.
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